James R. Lisa

Bio: James R. Lisa is an academic researcher. The author has contributed to research in topics: Carcinoma & Prostate. The author has an hindex of 3, co-authored 4 publications receiving 41 citations.

Treatment of malignant Leydig cell tumor.

Abstract: Malignant Leydig cell tumors (LCT) are rare. Only 32 cases of malignant LCT (as evidenced by metastatic spread) were reported. Generally metastatic spread occurs within 2 years of the primary LCT, and the patient dies within 2 years of the discovery of metastatic disease. The tumor is highly resistant to both radiation and chemotherapy. It also has a great propensity for recurring after surgical resection. A case is reported of a patient whose metastatic disease occurred 8 years after his primary LCT had been resected. He was treated with doxorubicin and mitotane without response. The clinical features of this case are highlighted, and a review of the literature describing treatment of this rare disease is presented.

Interstitial cell tumors of the testis: report of three new cases

Abstract: The interstitial cells of the testicle, which were first described by Leydig1in 1850, may rarely give rise to tumors, some of which are accompanied with endocrine changes. These cells have been regarded generally as the primary source of androgen. The study of such tumors is of interest, therefore, and may contribute to the knowledge of the normal endocrine physiology of the testis. This paper is concerned primarily with a review of the hormonal manifestations described in the previously reported cases of interstitial cell tumor and a report of 3 new cases, in which the patients were adults, one of whom had gynecomastia. In addition, we have elaborated certain criteria for the recognition of these tumors. LITERATURE Several comprehensive reviews of the literature of interstitial cell neoplasia have been published recently, notably by Jemerin,2Fialho3and Warren and Olshausen.4However, these writers and others have disagreed